Stock fact sheet · data as of
Actinium Pharmaceuticals, Inc. (ATNM): fair value, margin of safety and Wheel Score
Healthcare · Biotechnology · United States · Value
Is ATNM undervalued?
ATNM has a margin of safety of 67%: the stock closed at 1.06 on 16 Oct 2026 against a GLS average fair value of 3.20. 5 of the 6 valuation models that produced a number sit above the price. Our screens treat a discount this large as a strong starting point for a cash-secured put, not as a verdict - the fair value is a model output, and a wide gap can mean the models are missing something the market knows.
The 6 models disagree widely: GLS Growth gives 1.05 while Graham Growth gives 7.52. A spread that wide means the average is sensitive to which methods you trust; the model table below shows where each one lands, and the Quote page lets you switch any of them off.
The nightly engine files ATNM under Value: positive earnings at a P/E of 18 or less.
Nine valuation models for ATNM
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | 1.48 | +40% | Present value of the projected free cash flows, discounted at the cost of capital |
| Graham Number | 2.80 | +164% | The most a defensive investor pays for the earnings and book value per share |
| Graham Growth | 7.52 | +610% | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields |
| Lynch | 2.32 | +119% | EPS × the earnings growth rate (PEG of 1), growth capped at 25% |
| GLS Growth | 1.05 | -1% | EPS compounded ten years at the blended growth rate, discounted back at 15% a year |
| 10 Cap | - | - | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight |
| Payback Time | - | - | Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | 4.00 | +278% | Earnings power value: current EPS capitalised at 9% with no growth |
| Zombie (liquidation) | 0.1730 | -84% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 11.07 | +944% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Financial health is weak: ATNM passes 4 of the nine Piotroski tests. Our screens drop the stock at the health rule; a low score is often the reason a stock looks cheap on the valuation models. The GLS Moat score is low at 1.9 out of 10, which says the ten-year record of revenue, earnings, margins and returns on capital has been inconsistent - growth and shocks rather than steady compounding.
Returns on capital are thin or negative - ROIC -355.7%, ROE -432.6%, ROA -65.5% - with debt at 0.22 times equity and negative free cash flow.
Actinium Pharmaceuticals, Inc. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from License 100% (quarter Q2 FY2026).
Institutional ownership scores 2/10, insider activity 5/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 4 / 9 | ROIC | -355.7% |
|---|---|---|---|
| GLS Moat | 1.9 / 10 | ROE | -432.6% |
| Debt / equity | 0.22 | ROA | -65.5% |
| Free-cash-flow yield | -69.8% | Payout ratio | 0% |
| Institutions | 2 / 10 | Insiders · Congress | 5 · 5 / 10 |
Wheel Score 49: Weak
ATNM scores 49 out of 100 on the Wheel Score, in the Weak band (under 50). Value 25/25, Health 9/20, Moat 3/15, Premium 5/20, Stability 7/20. The score is not a judgement on the company; it says the price, quality and premium do not line up for selling puts on it today.
Implied volatility is 214%, far above the range the wheel strategy is built for. The premium looks generous; the Wheel Score gives it only 5 of 20 Premium points because moves of that size can blow through any strike. Chain open interest is 3,453 contracts across all expiries - enough for the wheel at normal size.
Volume runs at 143k shares a day on a market cap of $33M, with a beta of 0.02 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score gives that 7 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 25 / 25 | 67% margin of safety | |
| Health | 9 / 20 | Piotroski 4/9 | |
| Moat | 3 / 15 | moat 1.9/10 | |
| Premium | 5 / 20 | implied volatility 214% | |
| Stability | 7 / 20 | 143k shares/day, $33M cap, beta 0.02 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
The next earnings report is due on 13 Nov 2026, 28 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Biotechnology
The 12 companies below are the closest to Actinium Pharmaceuticals, Inc. by market cap within the Biotechnology industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| ALGS Aligos Therapeutics, Inc. | 5.39 | 0.1520 | -3446% | 12No options | $34M |
| IRLA IRulya Therapeutics Inc. | 33.23 | - | - | 25Weak | $34M |
| BCTX BriaCell Therapeutics Corp. | 3.77 | 4.14 | +9% | 29No options | $33M |
| ELTX Elicio Therapeutics, Inc. | 1.78 | 0.2252 | -691% | 15Weak | $34M |
| CRVO CervoMed Inc. | 2.25 | 0.8036 | -180% | 15No options | $34M |
| IXHL Incannex Healthcare Limited | 2.88 | 4.02 | +28% | 37Weak | $34M |
| MGX Metagenomi, Inc. Common Stock | 0.8452 | - | - | 30No options | $32M |
| GRDX GridAI Technologies Corp. | 4.46 | - | - | 25No options | $32M |
| ELUT Elutia Inc | 0.7888 | 24.46 | +97% | 39No options | $35M |
| NNVC NanoViricides, Inc. | 1.37 | 1,583,177.91 | +100% | 45Weak | $35M |
| GRCE Grace Therapeutics, Inc. | 1.95 | 0.6964 | -180% | 23Weak | $32M |
| CLCS Cell Source, Inc. | 0.4649 | - | - | 26No options | $32M |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about ATNM
Is ATNM undervalued right now?
By the GLS models, yes: at 1.06 the stock is 67% below the average fair value of 3.20 (data as of 16 Oct 2026). Whether the discount is deserved is the question to research next.
What is the Wheel Score of ATNM and what does it mean?
ATNM scores 49 out of 100 (Weak). The Wheel Score blends the margin of safety (25 points), Piotroski health (20), the GLS moat (15), the option premium on offer (20) and trading stability (20) into one number that ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned. 80 and above is Prime, 65-79 Good, 50-64 Fair, under 50 Weak.
What is the GLS fair value for ATNM?
3.20 per share as of 16 Oct 2026 - the simple average of the 6 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Actinium Pharmaceuticals, Inc. report earnings next?
The next earnings report is due on 13 Nov 2026, 28 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.
Does ATNM have listed options, and how liquid are they?
Yes. The nightly snapshot found 30 listed contracts with 3,453 open interest across all expiries and implied volatility of 214% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.